Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1

Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 at other companies

APA
Artisan Partners Asset Management Inc.APAM
$8.39M-1.3%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$43.29M+43.3%
UFP Industries, Inc. logo
UFP Industries, Inc.UFPI
$8.47M-26.7%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
1.7%+0.5pp
Imax logo
ImaxIMAX
$5.79M+9.8%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$15.39M-43.8%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1?
BioCryst Pharmaceuticals (BCRX) reported sharebased compensation arrangement by sharebased payment award compensation cost1 of $16.03M in Q1 2026.
How has BioCryst Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1 changed year-over-year?
BioCryst Pharmaceuticals's sharebased compensation arrangement by sharebased payment award compensation cost1 decreased by 25.0% year-over-year, from $21.37M to $16.03M.
What does sharebased compensation arrangement by sharebased payment award compensation cost1 mean?
The total expense recognized in the income statement related to equity-based awards granted to employees and directors. This metric captures the non-cash cost of aligning employee incentives with shareholder interests through stock options, restricted stock, or similar instruments. Investors use this to assess the true cost of human capital and the potential for shareholder dilution.